Off Patent
May 2027

Janumet XR

metformin hydrochloride and sitagliptin phosphate

Merck Sharp and Dohme LLC a sub of Merck and Co Inc

Tablet, extended release (oral) · NDA 202270

Last listed protection ends
May 24, 2027

The FDA lists 1 patent for Janumet XR, and this is the day the last one ends. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Patent 7,326,708
    Claims the drug substance, the drug product and a use (U-1227)
  2. Patent 7,326,708
    Pediatric extension: six more months